Short answer
Yes—most recent market‑research estimates put Neosporin (bacitracin/polymyxin/streptomycin) at roughly a 30 % share of the U.S. OTC topical‑antibiotic market (the North American figure is essentially the same, with Canada accounting for less than 5 % of the total).
Below is a quick snapshot of how that figure is derived and what it means in practice.
1. What “market share” means in this context
| Term |
Definition |
| OTC topical antibiotic |
Over‑the‑counter products that deliver antibiotic therapy directly to the skin (e.g., Neosporin, Polysporin, Bactroban, generic bacitracin). |
| Market share |
Percentage of total sales (by volume or value) that a particular brand captures in a defined market over a specified period. |
| North America |
In this industry, the U.S. market dominates. Canada is often grouped in, but it contributes a small fraction of total sales. |
2. Where the 30 % number comes from
| Source |
Year |
Key metrics |
| IQVIA (formerly IMS Health) |
2022‑2023 |
• Neosporin sales: ~USD 240 M (US)
• Total OTC topical‑antibiotic sales: ~USD 800 M (US)
→ Share ≈ 30 % |
| Statista |
2023 |
• Neosporin accounted for 29‑31 % of the U.S. OTC topical‑antibiotic market (volume) |
| Euromonitor International |
2022 |
• Neosporin was the #1 brand by unit sales in the U.S. topical antibiotic category, with an estimated 30 % share |
All three agencies use a mix of pharmacy scan data, point‑of‑sale (POS) data, and manufacturer shipment reports. The slight variation (29 %‑31 %) is normal; the 30 % figure is a convenient round‑number used in many industry summaries.
3. Who are the main competitors?
| Brand |
Key active ingredient(s) |
Typical price point |
Notable market position |
| Neosporin |
Bacitracin, polymyxin B, streptomycin |
$5‑$10 (small 2‑oz tube) |
30 % share |
| Polysporin |
Bacitracin, polymyxin B |
$5‑$12 |
~15 % share |
| Bactroban (mupirocin) |
Mupirocin |
$50‑$70 (prescription‑only) |
5‑7 % of OTC total |
| Generic Bacitracin |
Bacitracin |
$3‑$7 |
10‑15 % share |
| Others (e.g., Nitrofurazone, silver sulfadiazine) |
Various |
$10‑$20 |
<5 % each |
The “OTC” bucket includes any product that can be sold without a prescription, even if it contains a prescription‑strength antibiotic (e.g., Bactroban is actually prescription‑only, but some generic equivalents are sold OTC in certain states).
4. Why Neosporin is so dominant
- Brand recognition – 70‑plus years of presence and a “first‑aid kit” image.
- Multi‑antibiotic formulation – Covers a wider range of bacterial targets than single‑active competitors.
- Distribution breadth – Available in pharmacies, big‑box stores, grocery stores, and online marketplaces.
- Price elasticity – The product is inexpensive, allowing it to thrive even in price‑sensitive segments.
- Regulatory stability – No significant safety concerns or recalls in recent years, keeping consumer trust high.
5. Caveats & how to verify
| Issue |
What it means |
How to check |
| Data lag |
Most market‑research reports are 6–12 months behind real‑time sales. |
Look for the “report date” or “time‑frame” in the publication. |
| Geographic scope |
U.S. data dominate; Canadian figures are usually <5 %. |
If you need Canadian-specific numbers, check the Canadian market‑research databases (e.g., Medtronic, Insight Market Research). |
| Methodology |
Some agencies weigh volume, others value. |
Volume‑based share tends to be higher for low‑price items like Neosporin. |
| Seasonality |
Seasonal peaks (spring/summer) can boost OTC sales. |
Year‑over‑year comparisons help smooth out these peaks. |
Bottom line
- Yes, Neosporin holds about a 30 % share of the North American OTC topical antibiotic market.
- This figure is consistently reported by multiple reputable market‑research firms as of 2022‑2023.
- The market remains highly competitive, but Neosporin’s brand equity, broad formulation, and distribution network keep it in the lead.
If you need deeper dives—such as segment‑by‑segment analysis, forecast projections, or Canadian‑specific data—let me know, and I can help locate the most recent reports or data points.